Is cholesterol a risk factor for stroke? No

Archives of Neurology

Volumn 56, Issue 12, 1999, Pages 1521-1524

  Landau, William M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA TOCOPHEROL; C REACTIVE PROTEIN; CHOLESTEROL; CYANOCOBALAMIN; ESTROGEN; FAT; FIBRINOGEN; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NITRIC OXIDE; PRAVASTATIN; PROTEIN; PYRIDOXINE; SIMVASTATIN; STATIN;

ARTICLE; CLINICAL TRIAL; HUMAN; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; STROKE;

EID: 0032757216     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.56.12.1521     Document Type: Article

References (44)

1. Stedman's Medical Dictionary. 26th ed. Baltimore, Md: Williams & Wilkins; 1995.
2. Gordon T, Kännel WB. Multiple risk functions for predicting coronary heart disease: the concept, accuracy, and application. Am Heart J. 1982;103: 1031-1039.
3. Hopkins PN, Williams RR. Identification and relative weight of cardiovascular risk factors: risk for developing cardiovascular risk factors and adverse effects of riskfactor reduction. CardiolClin. 1986:4:3-31.
4. Taylor WC, Landau WM. Atherosclerosis and stroke [letter]. Ann Neurol. 1990:28:108.
5. Qizilbash N, Jones L, Warlow C, Mann J. Fibrinogen and lipid concentrations as risk factors for transient ischaemic attacks and minor ischaemic strokes. BMJ. 1991:303:605-609.
6. Benfante R, Yano K, Hwang L-J, Curb JD, Kagan A, Ross W. Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian Japanese men: implications of shared risk. Stroke. 1994:25:814-820.
7. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13.000 strokes in 450,000 people in 45 prospective cohorts, tancer. 1995:346:1647-1653.
8. HachinskiV,GraffagninoC, BeaudryM,étal. Lipids and stroke: a paradox resolved. Arch Neurol. 1996:53:303-308.
9. Dyker AG, Weir CJ, Kennedy RL. Influence of cholesterol on survival after stroke: retrospective study. BMJ. 1997:314:1584-1588.
10. Gillman MW, Cupples A, Willen BE, Ellison RC, Wolf PA. Inverse association of dietary fat with development of ischémie stroke in men. JAMA. 1997; 278:2145-2150.
11. Landau WM. In Book Review of: The Lipid Hypothesis of Atherogenesis by William E. Stehbens. Neurology. 1995:45:207-208.
12. Stehbens WE. Causality in medical science with particular reference to heart disease and atherosclerosis. PerspectBiolMed. 1992:36:97-119.
13. Stehbens WE. Lipids and atherosclerosis: an impossible causal relationship. Am Clin Lab. 1997; 16:18-20.
14. Fagard R. Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Pressure in the Elderly, xlmj/Wed. 1991;90:628635.
15. Weverling-Rijnsburger AWE, Blauw GJ, Lagaay AM, Knook DL, Meinders AE, Westendorp RGJ. Total cholesterol and risk of mortality in the oldest old. Lancet. 1997;350:1119-1123.
16. Ravnskov U. Hypercholesterolemia does not cause coronary heart disease-evidence from the nephrotic syndrome. Nephron. 1994:66:356-357.
17. Enriquez-Sarano M, Klodas E, Garratt KN, Bailey KR, Tajik AJ, Holmes DR. Secular trends in coronary atherosclerosis: analysis in patients with valvular régurgitation. NEnglJMed. 1996:335:316-322.
18. Sutler MC. Cardiovascular controversies: blood cholesterol is not causally related to atherosclerosis. Cardiovasc Res. 1994;28:575.
19. Atkins D, Psaty BM, Koepsell TD, Longstreth WT, Larson EB. Cholesterol reduction and the risk for stroke in men: a meta-analysis of randomized, controlled trials. Ann Intern Med. 1993;119:136-145.
20. Hebert PR, Gaziano JM, Hennekens CH. An overview of trials of cholesterol lowering and risk of stroke. Arch Intern Med. 1995:155:50-55.
21. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). J.anceJ. 1994:344:1383-1389.
22. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. fJEngl JMed. 1995:333:1301-1307.
23. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N EnglJMed. 1996:335:1001 -1009.
24. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998: 279:1615-1622.
25. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N EnglJMed. 1998:339:1349-1357.
26. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older pa-tients with myocardial infarction and cholesterol levels in the average range: results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med. 1998:129:681-689.
27. Blauw GJ, Lagaay AM, Smelt AHM, Westendorp RGJ. Stroke, statins, and cholesterol: a metaanalysis of randomized, placebo-controlled doubleblind trials with HMG-CoA reductase inhibitors. Stroke. 1997;38:946-950.
28. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. JAMA. 1997:278:313-321.
29. Crouse JR III, Byington RP, Furberg CD. HMGCoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. Atherosclerosis. 1998:138:11-24.
30. Treasure CB, Klein LJ, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. NEnglJMed. 1995:332:481-487.
31. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterollowering and antioxidant therapy on endotheliumdependent coronary vasomotion. NEnglJMed. 1994:332:488-493.
32. KaesemeyerWH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. JAm Coll Cardiol. 1999:33:234-241.
33. John S, Schlaich M, Langenfeld M, et al. Increased bioavailability of nitric oxide after lipidlowering therapy in hypercholesterolemic patients. Circulation. 1998:98:211-216.
34. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for car-diovascular event reduction. JAMA. 1998;379: 1643-1650.
35. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase (cerebral blood flow/cerebral ischemia). Proc NatlAcad Sei USA.] 993:95:8880-8885.
36. Taylor WC, Pass TM, Shepard DS, Komaroff AL Cholesterol reduction and life expectancy: a model incorporating multiple risk factors. Ann Intern Meet. 1987;106:605-614.
37. National Center for Health Statistics. Vital Statistics of the United States, 7S92[table 5-2]. Washington, DC: US Public Health Service; 1996;2(pt A).
38. Hegsted DM, Nicolosi RJ. Individual variation in serum cholesterol levels. Proc rJatl Acad Sei USA. 1987:84:6259-6261.
39. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ. 1990:301:309-314.
40. Mann GV, ed. Coronary Heart Disease: The Dietary Sense and Nonsense-An Evaluation by Scientists. London, England: Janus; 1993.
41. Walsh JME, Grady D. Treatment of hyperlipidemia in women. JAMA. 1995:274:1152-1168.
42. Ebrahim S, Smith GO. Systematic review of randomised controlled trials of multiple risk factor interventions for preventing coronary heart disease. BMJ. 1997;314:1666-1674.
43. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a crossnational study. JAMA. 1998:279:1458-1462.
44. ForrowLJaylorWC.Amold RM. Absolutely relative: how research results are summan'zed can affect treatment decisions. Am J Med. 1992;92:121 -124.